6-Ketoprostaglandin F1 alpha (6 Ketoprostaglandin F1 alpha)

The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.

Also Known As:

6 Ketoprostaglandin F1 alpha; 6 Keto PGF1 alpha; 6 Oxo PGF1 alpha; 6 Oxoprostaglandin F1 alpha; F1 alpha, 6-Ketoprostaglandin; F1 alpha, 6-Oxoprostaglandin; alpha, 6-Keto-PGF1; alpha, 6-Ketoprostaglandin F1; alpha, 6-Oxo-PGF1; alpha, 6-Oxoprostaglandin F1; 6-Keto-PGF1 alpha; 6-Oxo-PGF1 alpha; 6-Oxoprostaglandin F1 alpha; Prost-13-en-1-oic acid, 9,11,15-trihydroxy-6-oxo-, (9alpha,11alpha,13E,15S)-

Networked: 550 relevant articles (19 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lei, Ting: 1 article (02/2008)
2.	Wang, Chao: 1 article (02/2008)
3.	Wang, Laizang: 1 article (02/2008)
4.	Wang, Zhi: 1 article (02/2008)
5.	Zhang, Weiguang: 1 article (02/2008)
6.	Bavbek, N: 1 article (04/2005)
7.	Birdane, A: 1 article (04/2005)
8.	Büyükaşik, Y: 1 article (04/2005)
9.	Dündar, S V: 1 article (04/2005)
10.	Haznedaroğlu, I C: 1 article (04/2005)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/01/1990 - "There is a relationship between severity of bacterial bronchial asthma clinical symptoms and plasma 6-keto-PGF1 alpha, TxB2: in moderate disease against grave one as well as in clinical versus subclinical forms (remission) relevant indices are reduced. " 04/01/1988 - "To define its activity on human airways we have studied the effects of doubling concentrations of inhaled PGI2 and its hydrolysis product 6-oxoprostaglandin F1 alpha (6-oxo-PGF1 alpha) on specific airway conductance (sGaw), maximum expiratory flow at 30% vital capacity (Vmax30), forced expiratory volume in 1 s (FEV1), and static lung volumes in subjects with mild allergic asthma. " 01/01/1993 - "Severe asthma remission is characterized by higher levels of 6-keto-PGF1 alpha and TxB2 than moderate asthma one, demonstrates a tendency to growing PGF2 alpha levels. " 01/01/1993 - "The study revealed the relation of bronchial asthma (bacterial variant) clinical pattern to plasma levels of PGF2 alpha, 6-keto-PGF1 alpha and TxB2. " 09/01/2000 - "Experimental study of guinea pig with asthma model showed that CBKCP could markedly prolong the latent time of asthma attack, lower the percentage of mast cells in total cells in the alveoli lavage solution, blood acidophic cell count and degranulation rate of mast cells, and decrease IgE, IL-4 and TXB2 levels as well as increase the 6-keto-PGF1 alpha level. "
2.	Pulmonary Edema 02/01/2002 - "Rats of different groups were drowned nearly to death in hypothermic sea water and then taken out of the water rapidly, observed at room temperature, after that the following steps were taken in 5, 15, 30, 60, 240 min and 360 min groups, that were 1 ml arterial blood taken from left heart for blood-gas analysis including pH, PaO2 and PaCO2, rectal temperature observed; at last, the ratio of left dry lungs with left wet lungs was assessed, TXB2 and 6-Keto-PGF1 alpha in right lungs were examined in all above groups and dead group(14 rats dead, only 4 examined). " 04/15/1993 - "NAC treatment significantly improved survival of endotoxin treated rats, ameliorated structural lung damage, diminished lung wet weight and lung albumin leakage, lowered lung perfusate TXB2 and 6-keto-PGF1 alpha levels and slightly improved vasocontractility in isolated perfused lungs. " 01/01/1987 - "We studied lung clearance of aerosolized technetium-labeled diethylenetriamine pentaacetic acid (99mTcDTPA), plasma concentrations of 6-keto-PGF1 alpha and thromboxane B2, and pulmonary edema as indices of lung injury in rabbits exposed to cigarette smoke (CSE). " 10/01/1990 - "Endotoxin caused hemoconcentration, granulocytopenia, decreased cardiac index, systemic hypotension, pulmonary hypertension, increased pulmonary vascular resistance, bronchoconstriction, hypoxemia, increased permeability of the alveolar-capillary membrane, pulmonary edema, and increased plasma concentrations of thromboxane B2 (TxB2), prostaglandin F2 alpha (PGF2 alpha), and 6-keto-PGF1 alpha. "
3.	Lung Injury 03/01/1991 - "Addition of a thromboxane synthetase inhibitor (U 63557A) reduced lung injury as well as TxB2 formation without affecting the production of 6-keto-PGF1 alpha. " 03/01/1991 - "Addition of the cyclooxygenase inhibitors, indomethacin, or flubiprofen to the lung perfusate before and after ischemia inhibited lung injury as well as the production of 6-keto-PGF1 alpha and TxB2. " 01/01/1987 - "We studied lung clearance of aerosolized technetium-labeled diethylenetriamine pentaacetic acid (99mTcDTPA), plasma concentrations of 6-keto-PGF1 alpha and thromboxane B2, and pulmonary edema as indices of lung injury in rabbits exposed to cigarette smoke (CSE). " 01/01/1988 - "We studied lung clearance of technetium-labeled diethylenetriamine pentaacetic acid [( 99mTc]DTPA), plasma and bronchoalveolar lavage fluid (BALF) concentrations of 6-keto-PGF1 alpha (stable metabolite of prostacyclin, prostaglandin I2, PGI2), TxB2 (stable metabolite of thromboxane A2, TxA2), and leukotriene B4 (LTB4), and inflammatory cells as indices of lung injury in rabbits exposed to cigarette smoke (CSE). "
4.	Ureteral Obstruction 02/01/1989 - "With the degree of ureteral obstruction becoming more severe, the output of PGE2 increased, while that of 6-keto-PGF1 alpha and TxB2 decreased. " 08/01/1991 - "Isolated glomeruli from rats with bilateral ureteral obstruction (BUO) of 24-h duration produced significantly greater amounts of prostaglandin (PG) E2 and 6-keto-PGF1 alpha in vitro than glomeruli from sham-operated control (SOC) rats. " 07/01/1993 - "Glomeruli isolated from rats with bilateral ureteral obstruction (BUO) of 24 hr duration produced significantly greater amounts of prostaglandin (PG) E2, 6-keto-PGF1 alpha, thromboxane B2, and leukotriene B4 than glomeruli isolated from sham-operated control (SOC) rats. "
5.	Ischemia 04/01/1999 - "Ischemia and reperfusion markedly increased the release of 6-keto-PGF1 alpha and TXB2. " 03/01/1995 - "The results showed that TXB2 and cAMP contents in brain tissues and the latter in plasma markedly increased (P < 0.05, P < 0.01), the 6-keto-PGF1 alpha in brain tissues significantly lowered (P < 0.05) in ischemia formed 30 minutes and 45 minutes after reperfusion. " 01/01/1995 - "The results indicate that the TXB2 levels after drug treatment were lower than those in ischemia control rats, but the 6-keto-PGF1 alpha levels showed no obvious difference between the two groups. " 01/01/1992 - "In addition, they indicate that the thresholds (duration of ischemia) for the postischemic production and the temporal profiles of TxB2 and 6-keto-PGF1 alpha in the caudate and hippocampus differ. " 01/01/1992 - "6-Keto-PGF1 alpha levels increased in only the group subjected to 20 min of ischemia and, by contrast to the pattern of TxB2 change, 6-keto-PGF1 alpha levels remained elevated throughout the reperfusion period. "

Related Drugs and Biologics

1.	Thromboxane B2
2.	Prostaglandins
3.	Leukotriene B4
4.	Epoprostenol (Prostacyclin)
5.	salicylhydroxamic acid (SHAM)
6.	Technetium (Technetium 99m)
7.	Smoke
8.	Pentetic Acid (DTPA)
9.	Albumins
10.	Thromboxane A2 (A2, Thromboxane)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Tourniquets
3.	Pancreas Transplantation
4.	Renal Dialysis (Hemodialysis)
5.	Intravenous Infusions